NFT Limited releases verification protocol for digital commerce

The article highlights Primaris REIT (TSX:PMZ.UN) and Minto Apartment REIT (TSX:MI.UN) as Canadian real-estate dividend plays tied to housing-cycle shifts. Primaris reported Q1 2026 net income of $41.9M, FFO per diluted unit of $0.425, and $0.88 annualized distribution (~4.5% yield). Minto reported Q1 2026 revenue of $39.4M (+3.7%) and normalized FFO/unit of $0.2371 (+7.4%), but occupancy fell to 93.7%. It also notes Crestpoint agreed to buy Minto units for $18 cash, expected in H2 2026.

AbCellera Biologics (ABCL) plans to advance its hot-flash drug, ABCL635, into Phase 3 trials after promising Phase 2 results. The company is modeling dosing and engaging in regulatory discussions with the FDA. ABCL635 showed sleep-score results comparable to Bayer's LYNKUET, according to the company. AbCellera is also developing other candidates, including ABCL992, a longer-acting version of ABCL635.

AMD and PsiQuantum expanded their partnership to build infrastructure for fault-tolerant quantum computers. AMD will take an equity stake in PsiQuantum, but the amount was not disclosed. The collaboration focuses on hybrid quantum-classical applications and AI, with initial targets in drug discovery. AMD provides CPUs, GPUs, FPGAs, and ROCm software, while PsiQuantum contributes photonic quantum technology.

Vivani Medical (NASDAQ:VANI) reported Phase 1 trial results for NPM-139, a semaglutide implant for weight management. The trial showed no adverse events in the NPM-139 group, with similar weight loss to Wegovy. Vivani plans to advance to Phase 2 trials in 2027 and explore development in new patient groups. The company collaborates with Novo Nordisk on the technology.

electroCore Inc. (NASDAQ:ECOR) published results from a study on non-invasive neuromodulation for long COVID, showing symptom improvements in active intervention groups compared to controls. The study, funded by the U.S. Department of Defense, had limitations and requires further confirmation. Neither technology is FDA-approved for this use.

AMD will invest in PsiQuantum to develop quantum computing infrastructure. The partnership aims to combine AMD's CPUs, GPUs, and AI tech with PsiQuantum's silicon photonics platform. The investment size was not disclosed. PsiQuantum's drug research tech is already using AMD hardware, showing promising results in drug discovery.